J&J Inks $1B Deal To Acquire Aragon Pharmaceuticals

Law360, New York (June 17, 2013, 2:03 PM EDT) -- Johnson & Johnson plans to acquire California-based Aragon Pharmaceuticals Inc. in a deal worth up to $1 billion, the companies said on Monday, in an agreement that the New Jersey pharmaceutical giant hopes will boost its efforts in prostate cancer drug development.

Under the agreement, Johnson & Johnson will pay $650 million in cash for Aragon, as well as a possible $350 million in additional payments if Aragon meets certain growth milestones, the company said in a statement. Included in the acquisition is Argon's androgen receptor...
To view the full article, register now.